# Amgen Inc. (AMGN)

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/AMGN/primer

## Business Model

---
ticker: AMGN
step: 01
generated: 2026-05-12
source: quick-research
---

### Amgen Inc. (AMGN) — Business Overview

#### Business Description
Amgen is one of the world's largest biopharmaceutical companies, with a portfolio of 14 products generating $1B+ in annual sales. After the $28B Horizon Therapeutics acquisition (closed October 2023), Amgen expanded its rare disease franchise (TEPEZZA, KRYSTEXXA, UPLIZNA, TAVNEOS). The most important asset in the pipeline is MariTide — an obesity drug positioned for monthly/quarterly dosing vs. weekly GLP-1 leaders Wegovy + Zepbound, with Phase 3 readouts expected in 2027. CEO Robert Bradway has been at the helm since 2012.

#### Revenue Model
- **Biologics (primarily injectable, ~85% of revenue):** Anti-PCSK9 (Repatha), bone (Prolia, XGEVA, EVENITY), inflammation (Otezla, Enbrel), oncology/hematology (BLINCYTO, KYPROLIS, Vectibix, IMDELLTRA), rare diseases (TEPEZZA, KRYSTEXXA, UPLIZNA, TAVNEOS)
- **Biosimilars (~10%):** Mvasi, Kanjinti, Amgevita, Wezlana, Riabni (oncology + immunology biosimilars to other companies' originators)
- **Other/Royalties (~5%):** Royalties from licensing partnerships

#### Products & Services

##### Cardiovascular / Metabolic (Growth Drivers)
- **Repatha (PCSK9):** $876M Q1 2026 (+34% YoY) — fastest growing product; primary prevention indication expanding
- **MariTide (obesity, Phase 3):** Long-acting GIPR antagonist + GLP-1 agonist; monthly or quarterly dosing potential

##### Bone Health (Declining post-LOE)
- **Prolia (denosumab, osteoporosis):** -28% in 2026 — biosimilar entry
- **XGEVA (denosumab, oncology):** -39% in 2026 — biosimilar entry
- **EVENITY:** Anabolic for severe osteoporosis — growing 30%+

##### Inflammation / Immunology
- **Enbrel (etanercept):** Older TNF; Medicare price negotiations effective 2026
- **Otezla (apremilast):** Psoriasis/PsA — facing European generic Jan 2026
- **TEZSPIRE:** Asthma (anti-TSLP) — record growth +30%+

##### Oncology / Rare Disease
- **TEPEZZA (Horizon):** Thyroid eye disease — $1.9B FY25
- **KRYSTEXXA (Horizon):** Refractory gout — $1.2B FY25
- **UPLIZNA:** NMOSD
- **TAVNEOS:** ANCA-associated vasculitis
- **BLINCYTO, KYPROLIS, Vectibix:** Hematology/oncology
- **IMDELLTRA (tarlatamab):** BiTE small cell lung cancer

##### MariTide Phase 3 Program
- **MARITIME-1 + MARITIME-2:** Chronic weight management, 72-week monthly dosing
- **MARITIME-CV:** Cardiovascular outcomes
- **MARITIME-HF:** Heart failure + CV risk
- Six global Phase 3 studies; data 2027

#### Customer Base & Go-to-Market
- **Patients:** Millions globally with cardiovascular, autoimmune, oncology, rare disease conditions
- **Specialists + Hospitals:** Cardiologists, rheumatologists, endocrinologists, ophthalmologists, oncologists, geneticists
- **Payers:** US PBMs/insurers, ex-US single-payer systems
- **Channel:** Direct specialty + biotech sales force
- **Geographic mix:** ~75% US, ~25% International

#### Competitive Position
Amgen has multiple top-3 positions in major therapy areas: #1 in PCSK9 (Repatha vs Praluent), #1 in cardiovascular cholesterol biologics, leading bone health franchise (despite biosimilar pressure), strong oncology biologic franchise. MariTide's monthly dosing positioning is critical differentiation vs. Wegovy/Zepbound weekly injections. Competitors: Lilly (Mounjaro/Zepbound + cardiometabolic), Novo Nordisk (Wegovy/Ozempic), AbbVie (immunology), Roche/Sanofi (multiple), Vertex (cardio + rare).

#### Key Facts
- Founded: 1980 (Applied Molecular Genetics) in Thousand Oaks, CA
- Headquarters: Thousand Oaks, CA
- Employees: ~25,000
- Exchange: NASDAQ
- Sector / Industry: Health Care / Biotechnology
- Market Cap: ~$165B (May 2026)
- CEO: Robert A. Bradway (since 2012)
- Dividend: $9.96 annual ($2.49 quarterly)
- 13+ consecutive years of dividend growth
- 14 products generating $1B+ each

## Financial Snapshot

---
ticker: AMGN
step: 04
generated: 2026-05-12
source: quick-research
---

### Amgen Inc. (AMGN) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2023 | FY2024 | FY2025 | YoY |
|--------|--------|--------|--------|-----|
| Revenue | $28.2B | $33.4B | $36.8B | +10% |
| Product Sales | $26.9B | $32.3B | $35.6B | +10% (volume +13%, price -3%) |
| Adj. Gross Margin | 76% | 75% | 75% | flat |
| Adj. Operating Margin | 49% | 48% | 49% | +1pp |
| Adj. Net Income | $10.3B | $10.5B | $11.5B | +10% |
| Adj. EPS (diluted) | $18.65 | $19.50 | $21.40 | +10% |
| Free Cash Flow | $7.4B | $11.1B | $12.3B | +11% |

#### Q1 2026 Highlights

| Metric | Q1 2026 | YoY |
|--------|---------|-----|
| Revenue | $8.6B | +6% |
| Product Sales | $8.4B | +5% |
| 6 Growth Drivers Combined | $5.6B | +24% |
| Prolia + XGEVA Combined | $1.1B | -32% (biosimilar) |

#### Top Products (FY2025)

| Product | Sales | YoY |
|---------|-------|-----|
| Repatha | ~$3.3B | +34% |
| Enbrel | ~$3.0B | low single digit (Medicare price reset) |
| Prolia | ~$4.5B | flat (biosimilar entry late) |
| Otezla | ~$2.0B | flat (EU generic Jan 2026) |
| TEPEZZA | $1.9B | +mid teens |
| KRYSTEXXA | $1.2B | +20% |
| TEZSPIRE | $1.0B+ | +30% |
| BLINCYTO | $1.3B | +15% |
| EVENITY | ~$1.5B | +30% |

#### Cash Flow & Balance Sheet (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$14B |
| Capital Expenditures | ~$1.5B |
| Free Cash Flow | $12.3B |
| Cash & Investments | ~$10B |
| Total Debt | ~$60B (post-Horizon) |
| Net Debt/EBITDA | ~2.7x — elevated, deleveraging in progress |

#### Key Ratios (approximate, May 2026)
- P/E (forward): ~13x | EV/EBITDA: ~12x | Dividend Yield: ~3.3%
- ROIC: ~10% (pre-Horizon synergies)
- FCF Margin: ~33%

#### Growth Profile
FY25 revenue +10% to $36.8B; FY26 guidance raised to $37.1-38.5B (midpoint +3%) — sharp deceleration from +10% to +3% as biosimilar headwinds hit. Six growth drivers (Repatha, EVENITY, TEZSPIRE, TEPEZZA, KRYSTEXXA, BLINCYTO) growing 24% YoY collectively. Prolia + XGEVA combined -32%. The math: growth engines need to keep outpacing LOE drag, plus MariTide needs to launch successfully late 2027/2028.

#### Forward Estimates
- **FY2026E Revenue:** $37.1-38.5B (mgmt guide; +1-5%)
- **FY2026E Adj EPS:** $21.70-23.10 (mgmt guide; +1-8%)
- **FY2027E EPS:** ~$24 (assumes MariTide approval visibility)
- **MariTide peak sales (bull):** $10B+
- **2030 Bull Target:** $450-550 if MariTide Phase 3 succeeds + Repatha primary prevention

#### Capital Return
- Dividend $9.96 annual = ~$5.4B paid
- 13+ consecutive years of dividend growth
- Buybacks moderated for Horizon debt paydown
- Total return: ~3.3% dividend + future buyback resumption

## Recent Catalysts

---
ticker: AMGN
step: 12
generated: 2026-05-12
source: quick-research
---

### Amgen Inc. (AMGN) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **MariTide — monthly/quarterly obesity dosing differentiation** — MariTide's potential edge over Novo Wegovy + Lilly Zepbound (weekly injections) is its monthly or quarterly dosing capability. Phase 2 maintenance data showed sustained weight loss with lower doses taken monthly/quarterly. Six Phase 3 studies underway (MARITIME-1, -2, -CV, -HF). Data 2027. Peak sales bull case: $10B+. If approved with monthly dosing, MariTide could capture 20-30%+ of GLP-1-naive patients who reject weekly injections.

2. **Six growth drivers +24% YoY offsetting LOE drag** — Repatha (+34%, Q1 sales $876M record), EVENITY, TEZSPIRE, TEPEZZA, KRYSTEXXA, BLINCYTO collectively delivered $5.6B in Q1 2026 (+24% YoY). Repatha primary prevention indication could expand the franchise to $6B+. This is a textbook biotech diversification — concentration risk is limited even though MariTide gets the headlines.

3. **3.3% dividend yield + 13-year growth track record** — Dividend $9.96/share annual yielding 3.3%. Combined with ~13x forward P/E, this is a relatively cheap defensive biotech with multiple growth options. As Horizon debt deleverages and MariTide data approaches, the multiple has room for re-rating.

4. **Horizon Therapeutics integration on track** — TEPEZZA $1.9B FY25, KRYSTEXXA $1.2B FY25 — adding ~$3B+ in rare disease revenue from the $28B acquisition. UPLIZNA + TAVNEOS contributing. Integration appears smooth — provides a defensive diversification away from osteoporosis biosimilar risk.

#### Bear Case Risks

1. **Biosimilar erosion accelerating — Prolia/XGEVA -32% combined** — Q1 2026: Prolia + XGEVA combined fell 32% YoY. Full 2026 forecast: Prolia -28%, XGEVA -39%. Combined these represented ~$6B FY24 — meaningful contribution. Enbrel under Medicare price negotiations effective 2026. Otezla facing European generics Jan 2026. The LOE wave is the most aggressive in biotech.

2. **MariTide Phase 3 timeline risk — "waiting year"** — Bernstein downgraded Amgen labeling 2026 as a "waiting year" — full Phase 3 results not expected until 2027. Any safety signal (GI, muscle wasting), missed endpoints, or competitive disclosures (Lilly orforglipron, Novo amycretin) could push MariTide thesis further out.

3. **FY26 revenue growth deceleration to 1-5%** — Management guides FY26 revenue $37.1-38.5B (midpoint +3%) — sharp deceleration from +10% in 2025. Implies growth drivers + Horizon barely outpace LOE drag. Bears worry this is a 2-3 year "growth gap" before MariTide launches.

4. **$60B debt + Horizon goodwill risk** — Net debt/EBITDA ~2.7x is elevated for a biotech. Horizon goodwill significant — any TEPEZZA competitive disruption (Viridian VRDN-001, etc.) could trigger impairment. Capital allocation flexibility constrained for next 2-3 years.

#### Upcoming Events

- **Q2 2026 earnings (July 2026)** — Repatha trajectory; biosimilar erosion pace; MariTide Phase 3 enrollment milestones
- **Q3 2026 earnings (October 2026)** — Otezla EU generic actual impact; pipeline updates
- **MariTide Phase 2 long-term extension data** — Throughout 2026
- **MariTide Phase 3 interim updates** — Any glimpse of monthly/quarterly dosing data
- **2027 — MariTide Phase 3 topline data** — The make-or-break event

#### Analyst Sentiment

Sell-side consensus is **Hold / Moderate Buy** — split views. Bulls (UBS, Seeking Alpha) see MariTide as game-changer, $450-550 by 2030. Bears (Bernstein Hold, "waiting year") focus on growth deceleration + biosimilar erosion. Average price targets in the $320-360 range vs. recent ~$310 trading levels (~3-15% upside). The stock is a binary 2027 MariTide bet — current consensus reflects modest upside without baking in either bull case.

#### Research Date
Generated: 2026-05-12

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/amgn
- Full research API: GET /api/v1/research/AMGN/memo
- Coverage universe: /stocks